Community post

FDA has cleared Adaptive Phage Therapeutics to start formally investigating use of its PhageBank™ to treat prosthetic joint infections. This gives APT the green light to start a phase 1/2 clinical trial in the first half of 2021 in collaboration with Mayo Clinic.